Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease-Reference-Cited by-全球学者库

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

Published:2019-05-18 Issue:6 Volume:15 Page:764-775
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Vergallo Andrea¹²³,Mégret Lucile⁴,Lista Simone¹²³,Cavedo Enrica¹²³,Zetterberg Henrik⁵⁶⁷⁸,Blennow Kaj⁵⁶,Vanmechelen Eugeen⁹,De Vos Ann⁹,Habert Marie‐Odile¹⁰¹¹¹²,Potier Marie‐Claude¹³,Dubois Bruno¹²³,Neri Christian⁴,Hampel Harald¹, ,

Affiliation:

1. Sorbonne UniversityGRC no 21Alzheimer Precision Medicine (APM)AP‐HPPitié‐Salpêtrière HospitalBoulevard de l'hôpitalParisFrance

2. Brain & Spine Institute (ICM)INSERM U 1127CNRS UMR 7225Boulevard de l'hôpitalParisFrance

3. Institute of Memory and Alzheimer's Disease (IM2A)Department of NeurologyPitié‐Salpêtrière HospitalAP‐HPBoulevard de l'hôpitalParisFrance

4. Sorbonnes UniversitéCNRS UMR 8256INSERM ERL U1164Team Compensation in Neurodegenerative diseases and Aging (Brain‐C)ParisFrance

5. Institute of Neuroscience and PhysiologyDepartment of Psychiatry and NeurochemistryThe Sahlgrenska Academy at the University of GothenburgMölndalSweden

6. Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden

7. Department of Molecular NeuroscienceUCL Institute of NeurologyLondonUK

8. UK Dementia Research InstituteLondonUK

9. ADx NeuroSciences NVGhentBelgium

10. Sorbonne UniversitéCNRSINSERMLaboratoire d'Imagerie BiomédicaleParisFrance

11. Centre pour l'Acquisition et le Traitement des ImagesParisFrance

12. AP‐HPHôpital Pitié‐SalpêtrièreDépartement de Médecine NucléaireParisFrance

13. ICM Institut du Cerveau et de la Moelle épinièreCNRS UMR7225INSERM U1127UPMCHôpital de la Pitié‐SalpêtrièreParisFrance

Funder

Agentschap Innoveren en Ondernemen

Centre Hospitalier Universitaire de Bordeaux

Sorbonne University Foundation

la Fondation pour la Recherche sur Alzheimer

Agency for Innovation and Technology

Flanders Innovation and Entrepreneurship

Swedish and European Research Councils

Medical Research Council

INSERM

CNRS

Sorbonne Université

AXA Research Fund

Fondation partenariale Sorbonne Université

Fondation pour la Recherche sur Alzheimer

Foundation Plan-Alzheimer

AVID

Lilly

Pfizer

Avid

MSD Avenir

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2019.03.009

Reference48 articles.

1. Plasma Biomarkers Predict Brain Amyloid‐beta Burden;Abbasi J.;JAMA,2018

2. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

3. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

4. Biomarkers in Alzheimer's disease drug development

5. Biomarker and Clinical Trial Design Support for Disease‐Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force;Cummings J.;J Prev Alzheimers Dis,2018

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia;International Journal of Molecular Sciences;2024-01-18

2. In-vivo diagnosis of cerebral amyloid angiopathy: an updated review;Current Opinion in Neurology;2023-12-01

3. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers;American Journal of Obstetrics and Gynecology;2023-11

4. Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics;Alzheimer's & Dementia;2023-10-31

5. Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial;Alzheimer's Research & Therapy;2023-10-23